Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

For those whose tumors also demonstrate HER2 amplification (extra copies of the HER2 gene), this therapy may be less effective. In the SWOG S1613 clinical trial comparing this standard therapy to ...

"From the excitement of identifying HER2 gene amplification and resultant protein overexpression as a targetable oncogene, through the development of drugs targeting HER2 amplification and ...

Tumors, such as some breast and ovarian cancers, can express the marker HER2. HER2 is responsible for cancer growth and is the target of existing therapies, such as the most commonly used type of ...

Sixty-five samples were analyzed by FISH for HER2 amplification, including all of the 26 equivocal (IHC 2+) tumors, the 15 positive (IHC 3+) tumors, and 24 samples with 1+ or cytoplasmic staining.